Metropolis Healthcare Ltd - 542650 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst / Institutional Investor meeting on March 10, 202210-03-2022
10-03-2022
Metropolis Healthcare Ltd - 542650 - Disclosures under Reg. 29(1) / 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) / 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for SMALLCAP World Fund, Inc.28-02-2022
Metropolis Healthcare Ltd - 542650 - Disclosures under Reg. 29(1) / 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) / 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for SMALLCAP World Fund, Inc.26-02-2022
Metropolis Healthcare Ltd - 542650 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcripts of Earning Call for Q3FY202224-02-2022
Metropolis Healthcare Ltd - 542650 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dr. Sushil Kanubhai Shah22-02-2022
Metropolis Healthcare Ltd - 542650 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst / Institutional Investor meetings21-02-2022
Metropolis Healthcare plunges 23% in two days on disappointing Q3 results
In Q4FY22, the company expects better profitability on account of higher QoQ volumes from large government contract and benefits of investments in digitization and marketing.15-02-2022
Q3FY22 Quarterly Result Announced for Metropolis Healthcare Ltd.
Metropolis Healthcare declares Q3FY22 result: Metropolis Healthcare Ltd. posts 7% YoY growth in Revenue to Rs. 293 crores Non-Covid revenue grew by 9% YoY to Rs. 244 crores Patient visits increased by 22% on YoY basis to 3.3 Mn in Q3FY22 No. of tests increased by 24% on YoY basis to 6.3 Mn in Q3FY22 Home-Visits test services now covered in more than 100 locations Declared interim dividend of Rs. 8 per share 27.5% EBITDA Margin (Before CSR, ESOP & Onetime acquisition cost) +25% YoY B2C Revenue Growth (Non-Covid) Rs. 41.2 Crs. Reported PAT “During Q3FY22, we are pleased to share that we have been able to grow our non-covid revenue despite sharp drop in volumes from a government contract. We have made increased investments in digital& marketing, manpower& customer experience initiatives in order to strengthen our brand. This has impacted margins which we believe is a shortterm phenomenon. Our focused cities performance and B2C contribution continues to witness healthy growth and is a testimony to our on-ground efforts and the acceptance of Metropolis Brand in the minds of consumers. We have also been able to successfully complete the acquisition of Hitech Diagnostics during Q3 which will enable us to scale up our business, improve the B2C revenue contribution and tap the value end of the market.” Ameera Shah, Promoter and Managing Director, Metropolis Healthcare Ltd. Result PDF14-02-2022
Metropolis Healthcare Ltd - 542650 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Submission of copy of Newspaper Advertisement dated February 12, 202212-02-2022
Metropolis Healthcare Ltd - 542650 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst / Institutional Investor meetings12-02-2022